Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ensem Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners. The workload is distributed across 2 distinct art units, indicating a lack of concentration in a single group.
KOSAR, ANDREW D is the busiest examiner, managing 1 pending office action. Each of the 2 examiners holds 1 pending action. The company is currently dealing with 2 different examiners in 2 different art units, requiring a strategy that accounts for multiple sets of examiner preferences.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| KRIANGCHAIVECH, KETTIP | 1 | 19.0% | +28.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18528393 | PROTEIN KINETIC ENSEMBLE PLATFORM FOR DISCOVERY OF BINDING POCKETS AND NOVEL LIGANDS | KRIANGCHAIVECH, KETTIP | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18600161 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | KOSAR, ANDREW D | — |
| 18528393 | PROTEIN KINETIC ENSEMBLE PLATFORM FOR DISCOVERY OF BINDING POCKETS AND NOVEL LIGANDS | KRIANGCHAIVECH, KETTIP | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18600161 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | KOSAR, ANDREW D | 1625 | §102DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18528393 | PROTEIN KINETIC ENSEMBLE PLATFORM FOR DISCOVERY OF BINDING POCKETS AND NOVEL LIGANDS | KRIANGCHAIVECH, KETTIP | 1686 | §101§102§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEnsem Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrew D Kosar has the most, with 1 of Ensem Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
